Featured Articles
Employers Targeted to Import Drugs for Employees
Self-insured employers are understandably concerned about the costs of pharmacy benefits for their employees.
There’s Something About Katie Kratka
For so many people, healthcare doesn’t begin in an exam room—it begins with anxiety.
FDA Grants Approval to Encorafenib for BRAF V600E–Mutated Metastatic Colorectal Cancer
On February 24, 2026, the FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adults with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, as determined by an FDA-authorized test.